About Chiron

At Chiron, we are revolutionizing regenerative medicine by addressing the urgent need for a safer, non-transgenic, and virus-free approach to producing tissue-specific adult stem cells (ASCs) for therapeutic purposes. Leveraging our patented Suspension-Induced Stem Cell Transition technology, we offer a groundbreaking solution for generating high-yield, tissue-specific ASCs directly from somatic cells without relying on transgenes or viral vectors.

Our innovative method eliminates the risks associated with traditional reprogramming techniques, providing a reliable and scalable source of ASCs for a wide range of stem cell-based therapies. By promoting cellular transformation in a unique suspension culture system, our technology ensures safety, efficiency, and compatibility for clinical applications, paving the way for advancements in tissue regeneration, disease modeling, and personalized medicine.

At Chiron, we are committed to delivering cutting-edge solutions that meet the highest standards of safety and efficacy, empowering healthcare providers and researchers to harness the full potential of stem cell technology to transform patient care. Join us as we lead the charge toward a safer and more effective future in regenerative medicine.